300003:SZSELepu Medical Technology (Beijing) Co., Ltd. Class A Analysis

Lepu Medical is trading at CNY 12.61, well below its 20‑day SMA of 13.62, 50‑day SMA of 15.19 and 200‑day SMA of 16.93, indicating a prolonged downtrend. The 14‑day RSI sits at 26.8, placing the stock in oversold territory, while the MACD line remains beneath its signal line, reinforcing bearish momentum. The price is hovering just above the computed support of 12.28 and far from the resistance at 14.77, suggesting limited upside in the near term. Volatility over the past 30 days is high at 35.9 % and the beta of 0.28 signals low market‑wide sensitivity but pronounced intra‑stock swings. Combined with an extreme‑greed market sentiment (Fear‑Greed Index 94), the technical picture is mixed, with downside risks outweighing short‑term gains.
Fundamentally, the stock’s trailing P/E of 28 is slightly above the industry average of 27.55, yet the forward P/E of 17.5 and a target mean price of 20.1 imply a substantial upside of roughly 60 % from current levels. A dividend yield of 2.36 % and a payout ratio of 66 % are attractive, but free cash flow of only CNY 70 million against a dividend outflow suggests limited sustainability. The company carries a high debt‑to‑equity ratio of 31.4, though its cash balance of CNY 3.99 billion provides a solid liquidity cushion. Operating margins remain healthy (gross 61.7 %, operating 24.1 %) despite a 3.7 % revenue contraction, supporting the view that the stock is currently undervalued relative to its cash‑rich balance sheet and growth potential.